Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors.
Bodaghi
B
B
Bui Quoc
E
E
Wechsler
B
B
Tran
T H C
TH
Cassoux
N
N
Le Thi Huong
D
D
Chosidow
O
O
Herson
S
S
Piette
J-C
JC
LeHoang
P
P
D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D009363:Neoplasm Proteins / Q000627:therapeutic use; D047889:Receptors, Tumor Necrosis Factor, Type II; D012189:Retrospective Studies; D016896:Treatment Outcome; D053319:Tumor Necrosis Factor Decoy Receptors; D014605:Uveitis / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D009363:Neoplasm Proteins; D047889:Receptors, Tumor Necrosis Factor, Type II; D053319:Tumor Necrosis Factor Decoy Receptors; D000069285:Infliximab